WOODCLIFF LAKE, N.J., Oct. 30, 2017 /PRNewswire/ -- Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for cognitive impairment and sleep disorders associated with mild to moderate stages of AD dementia.   

"Our poster on sleep-wake patterns includes baseline data derived by wrist actigraphy from a Phase 2 study of a novel treatment for Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Alzheimer's dementia patients," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "Through new and continued research, we aim to further understand how treating ISWRD can impact the quality of life for patients and their families."

Two other posters presented at the meeting will look the use of the International Shopping List Test (ISLT) as an objective cognitive assessment to select individuals with early Alzheimer's disease in clinical trials, including Eisai's Phase 3 trial of elenbecestat (E2609).                                   

The following data will be presented during poster sessions at the meeting:

Eisai is investigating the safety and efficacy of lemborexant in patients aged 60 to 90 with ISWRD and mild to moderate AD dementia. Discovered by Eisai, lemborexant is a dual orexin receptor antagonist that competitively binds to the two subtypes of orexin receptors. The orexin system is a major regulator of the sleep-wake system. Lemborexant is being jointly developed by Eisai and Purdue Pharma L.P.

ISWRD is a circadian rhythm sleep disorder characterized by numerous sleep bouts throughout the 24-hour period, disrupted nighttime sleep, and changing sleep and wake patterns from day to day.  It is a common comorbid condition in AD and other dementias, appears early in the course of disease, and is associated with many of the behavioral disturbances in AD/dementia patients (e.g., agitation, restlessness, wandering). 

Elenbecestat is Eisai's in-house discovered beta amyloid cleaving enzyme (BACE) inhibitor and is being jointly developed by Eisai and Biogen in two global Phase 3 clinical studies (known as MISSION AD1 and MISSION AD2) as a potential treatment for early Alzheimer's disease.

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such products will successfully complete clinical development or gain FDA approval.

About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

SOURCE Eisai Inc.